Pylarify (piflufolastat f 18)
Ended Awarded Last action
- Contract number
- 36C26225F0420
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $350,837
Award facts
- Contract value 100% obligated
- $350,837.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$154,384 | |
| Original award | $505,221 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 22 (VISN 22) awarded a $350,837.12 delivery order to Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for prostate cancer detection and localization. The contract is structured as a firm fixed-price delivery order with no set-aside designation and is scheduled for completion by October 31, 2025. Performance will occur at the contractor's facility in North Billerica, Massachusetts. This delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a master contract vehicle that establishes the pricing and terms for ongoing radiopharmaceutical procurement across the VA system.
Progenics Pharmaceuticals has established itself as a critical supplier of specialized nuclear medicine products to federal healthcare providers, with PYLARIFY serving as its primary offering for VA medical centers and Defense Health Agency facilities. The company maintains an extensive portfolio of blanket purchase agreements and indefinite delivery contracts across multiple Veterans Integrated Service Networks, along with a $290 million Federal Supply Schedule contract with VISN 12 extending through March 31, 2030. This delivery order represents one of over 150 individual federal awards the company has received, reflecting its established role as a trusted provider of diagnostic radiopharmaceuticals supporting oncology imaging programs across the VA healthcare system.
Quick answers
Who was awarded contract 36C26225F0420?
36C26225F0420 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 22 (Veterans Health Administration) on May 1, 2025.
How much is contract 36C26225F0420 worth?
The government has obligated $350,837 on 36C26225F0420.
Is contract 36C26225F0420 an order under another contract?
Yes. 36C26225F0420 is a delivery order under 36F79725D0093, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26225F0420 competed?
The extent of competition for 36C26225F0420 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award